Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

6	0	
	OMB Number:	3235-0287
	Estimated average	burden
	hours per response	: 0.5

STATEMENT C	DF	CHANGES	IN	BENEFICIAL	OWNERSHIP
-------------	----	---------	----	------------	-----------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			2. Issuer Name and Ticker or Trading Symbol <u>Pacira BioSciences, Inc.</u> [PCRX]	(Check all app Direc	ctor	10% Owner Other (specify below)	
			3. Date of Earliest Transaction (Month/Day/Year) 06/28/2024	belov belov	er (give title w) Chief Medical (
5401 WEST KENNEDY BOULEVARD, SUITE 890		ULEVARD, SUITE	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line) Form Form	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting		
(Street) TAMPA	FL	33609	Rule 10b5-1(c) Transaction Indication	Pers	on		
(City)	(State)	(Zip)	Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See	to a contract, instr Instruction 10.	ruction or written plan	n that is intended to	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Date		2A. Deemed Execution Date, if any			4. Securities Disposed Of			5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
	((Month/Day/Year)			Amount	(A) or Price		Owned Following Reported Transaction(s)	(I) (Instr. 4)	
Common Stock	06/28/2024		A ⁽¹⁾	v	437.271	(D) A	\$24.319	(Instr. 3 and 4) 99,306.746	D	
Common Stock	07/01/2024		F ⁽²⁾		914	D	\$28.46	98,392.746	D	
Common Stock	07/02/2024		S ⁽³⁾		2,836	D	\$28.25	95,556.746	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Dispo of (D (Instr	5. Number 6. Date Exercisable and Expiration Date (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		7. Titl Amou Secur Unde Deriv Secur 3 and	int of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v			Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents shares of common stock acquired under the issuer's employee stock purchase plan in June 2024.

2. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Remarks:



** Signature of Reporting Person Date

07/03/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.